electroCore Stock Forecast, Price & News

electroCore (NASDAQ:ECOR) Frequently Asked Questions

Is electroCore a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for electroCore in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" electroCore stock.
View analyst ratings for electroCore or view top-rated stocks.

What stocks does MarketBeat like better than electroCore?

Wall Street analysts have given electroCore a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but electroCore wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is electroCore's next earnings date?

electroCore is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for electroCore.

How can I listen to electroCore's earnings call?

electroCore will be holding an earnings conference call on Thursday, November 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were electroCore's earnings last quarter?

electroCore, Inc. (NASDAQ:ECOR) posted its quarterly earnings results on Thursday, August, 5th. The company reported ($0.06) EPS for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.05. The firm earned $1.27 million during the quarter, compared to analysts' expectations of $1.30 million. electroCore had a negative net margin of 425.79% and a negative trailing twelve-month return on equity of 79.02%.
View electroCore's earnings history.

How has electroCore's stock been impacted by COVID-19?

electroCore's stock was trading at $0.5874 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ECOR stock has increased by 59.6% and is now trading at $0.9372.
View which stocks have been most impacted by COVID-19.

What guidance has electroCore issued on next quarter's earnings?

electroCore updated its third quarter 2021 earnings guidance on Tuesday, October, 19th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.50 million-$1.50 million, compared to the consensus revenue estimate of $1.56 million.

What price target have analysts set for ECOR?

3 analysts have issued twelve-month target prices for electroCore's stock. Their forecasts range from $0.93 to $3.00. On average, they anticipate electroCore's stock price to reach $2.31 in the next twelve months. This suggests a possible upside of 146.5% from the stock's current price.
View analysts' price targets for electroCore or view top-rated stocks among Wall Street analysts.

Who are electroCore's key executives?

electroCore's management team includes the following people:

• Daniel S. Goldberger, Chief Executive Officer & Director (LinkedIn Profile)
• Michael Romaniw, Executive Vice President-Systems & Operations
• Brian M. Posner, Secretary, Chief Financial & Accounting Officer (LinkedIn Profile)
• Peter S. Staats, Chief Medical Officer
• Basit Qari, Vice President-Information & Digital Technology

Who are some of electroCore's key competitors?

Some companies that are related to electroCore include Edap Tms (EDAP), IRIDEX (IRIX), Second Sight Medical Products (EYES), Movano (MOVE), FONAR (FONR), Electromed (ELMD), BioSig Technologies (BSGM), ENDRA Life Sciences (NDRA), Soleno Therapeutics (SLNO), Yubo International Biotech (YBGJ), Fc Global Realty (FCRE), Precision Optics (PEYE), Helius Medical Technologies (HSDT), Viveve Medical (VIVE) and Nuwellis (NUWE).
View all of ECOR's competitors.

What other stocks do shareholders of electroCore own?

Based on aggregate information from My MarketBeat watchlists, some companies that other electroCore investors own include T2 Biosystems (TTOO), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Acasti Pharma (ACST), Onconova Therapeutics (ONTX) and OPKO Health (OPK).

When did electroCore IPO?

(ECOR) raised $64 million in an initial public offering on Friday, June 22nd 2018. The company issued 4,300,000 shares at $14.00-$16.00 per share. Evercore ISI and JMP Securities served as the underwriters for the IPO and BTIG was co-manager.

What is electroCore's stock symbol?

electroCore trades on the NASDAQ under the ticker symbol "ECOR."

How do I buy shares of electroCore?

Shares of ECOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is electroCore's stock price today?

One share of ECOR stock can currently be purchased for approximately $0.94.

How much money does electroCore make?

electroCore has a market capitalization of $65.13 million and generates $3.50 million in revenue each year. The company earns $-23.51 million in net income (profit) each year or ($0.59) on an earnings per share basis.

How many employees does electroCore have?

electroCore employs 45 workers across the globe.

What is electroCore's official website?

The official website for electroCore is www.electrocore.com.

Where are electroCore's headquarters?

electroCore is headquartered at 150 ALLEN ROAD SUITE 201, BASKING RIDGE NJ, 07920.

How can I contact electroCore?

electroCore's mailing address is 150 ALLEN ROAD SUITE 201, BASKING RIDGE NJ, 07920. The company can be reached via phone at (973) 290-0097 or via email at [email protected].